> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Supply Chain Security Toolkit Out
- URL: https://www.fdaweb.com/supply-chain-security-toolkit-out/
- Published: 2017-07-20T12:00:00.000Z
- Updated: 2026-09-14T22:35:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139180

CDER Office of Compliance deputy director **Ilisa Bernstein** says FDA has led a team of international partners for the last four years in creating the Supply Chain Security Toolkit for Medical Products. Writing in an *FDA Voice* blog [post](https://blogs.fda.gov/fdavoice/index.php/2017/07/keeping-the-u-s-prescription-drug-supply-chain-among-the-safest-in-the-world/?ref=fdaweb.com), Bernstein says that collaborators included regulators from the 21-nation Asia-Pacific Economic Cooperation (APEC) group, non-APEC countries, industry stakeholders, representatives from non-governmental organizations, international organizations, and academia.

“The goal of this collaboration was to develop strategies to better secure the medical product supply chain across APEC economies and around the world,” Bernstein writes. “We also aimed to enhance APEC members’ regulatory standards to secure national and global supply chains, and develop tools that regulators and industry can use for training and for implementing best practices.”

The kit is described as a comprehensive resource that covers the entire supply chain and lifecycle of medical products, from raw materials to patient use. It focuses on developing and implementing processes and procedures designed to enhance global medical product quality and supply chain security.

“The toolkit provides detailed information and resources related to track and trace, Internet sales, detection technology, and much more,” Bernstein says. “The toolkit can be used by industry stakeholders and regulators from around the globe to adopt best practices and to strengthen laws and regulations to protect customers from unsafe and substandard drug products. It also is a valuable training tool for regulators grappling with the complexities of keeping the supply chain safe.”